Scopus by Title (Ref)

1. Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex

- Nappi F. , et al.

2. Population Pharmacokinetic Models of Ampicillin–Sulbactam Among Adult Patients with Infectious Diseases: A Systematic Review

- Poornachandran M. , et al.

3. Assessing antibiotic utilization trends and outcomes in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections

- Pranjic A. , et al.

4. Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options

- Karampatakis T. , et al.

5. Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations

- de Souza J. , et al.

6. Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review

- Spernovasilis N. , et al.

7. Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?

- Munita J.M. , et al.

8. Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia

- Shein A.M.S. , et al.

9. A retrospective cohort analysis of factors influencing continuous antibiotic therapy with ampicillin

- Weber L. , et al.

10. Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence

- Choi S.J. , et al.

11. Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

- Franzone J.P. , et al.

12. Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

- Rafailidis P. , et al.

13. How to treat severe Acinetobacter baumannii infections

- Bouza E. , et al.

14. Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections

- Shields R.K. , et al.

15. The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial

- Mirjalili M. , et al.

16. The effectiveness of colistin/levofloxacin compared to colistin/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial

- Momenzadeh M. , et al.

17. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis

- Wang J.L. , et al.

18. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

- Paul M. , et al.

19. Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective

- Giacobbe D.R. , et al.

20. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?

- O'Donnell J.N. , et al.

21. Treatment of pulmonary infection of extensively drug-resistant acinetobacter baumannii with intravenous colistin sulfate combined with atomization: A case report

- Xue X. , et al.

22. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

- Wagenlehner F. , et al.

23. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis

- Liu J. , et al.

24. Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials

- Eljaaly K. , et al.

25. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives

- Karvouniaris M. , et al.